@ankit_tripathi – Cannt think of any direct implication for Gujarat Themis. One, they are not into the value chain of Bedaquiline. Two, Bedaquiline is second line/fall back treatment once Refapentine or Isoniazid efficacy stops.
Though should be positive for GTL customers like Lupin, Unichem or Mecleods who will get access to adjacent market (second line treatment) – at least in domestic market.
Thanks,
Tarun
| Subscribe To Our Free Newsletter |
